TransCode Therapeutics (RNAZ) News Today $0.38 +0.04 (+12.08%) (As of 02:28 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period TransCode Therapeutics: Buy Rating Backed by Strategic Focus and Promising Phase 1 StudyNovember 15, 2024 | markets.businessinsider.comTranscode Therapeutics Reports Increased Losses Amid Funding ChallengesNovember 15, 2024 | markets.businessinsider.comTranscode Therapeutics sends open letter to shareholdersNovember 13, 2024 | markets.businessinsider.comTransCode Therapeutics Announces Nasdaq Extension to Regain ComplianceNovember 5, 2024 | globenewswire.comTranscode announces SRC approval of second cohort in Phase 1 TTX-MC138 trialOctober 24, 2024 | markets.businessinsider.comTransCode Therapeutics (NASDAQ:RNAZ) Stock Quotes, Forecast and News SummaryOctober 22, 2024 | benzinga.comTransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted TechnologyOctober 10, 2024 | markets.businessinsider.comTransCode Therapeutics (NASDAQ:RNAZ) Stock, Insider Trading ActivitySeptember 27, 2024 | benzinga.comTransCode Therapeutics (NASDAQ:RNAZ) Stock, Short Interest ReportSeptember 27, 2024 | benzinga.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Quotes, Forecast and News SummarySeptember 20, 2024 | benzinga.comTransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic CandidateSeptember 17, 2024 | globenewswire.comTransCode reports progress in metastatic breast cancer treatmentSeptember 13, 2024 | uk.investing.comBuy Rating for TransCode Therapeutics Backed by NIH Grant and Promising Treatment EfficacySeptember 5, 2024 | markets.businessinsider.comTransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead CandidateSeptember 5, 2024 | globenewswire.comTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Phase 1 Clinical Trial InitiationAugust 15, 2024 | finanznachrichten.deTransCode Therapeutics Announces Phase 1 Clinical Trial InitiationAugust 15, 2024 | markets.businessinsider.comRNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q2 2024August 15, 2024 | investorplace.comTransCode Therapeutics, Inc. Announces Closing of Public OfferingJuly 24, 2024 | globenewswire.comWhy Transcode Therapeutics (RNAZ) Stock Is Down 60%July 24, 2024 | benzinga.comWhy Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?July 23, 2024 | investorplace.comBiotechnology (Industry) (^YH20610010)July 23, 2024 | finance.yahoo.comTransCode Therapeutics Prices Public Offering Of 10 Mln Shares At $0.30/shrJuly 22, 2024 | markets.businessinsider.comTransCode Therapeutics, Inc. Announces Pricing of Public OfferingJuly 22, 2024 | globenewswire.comTransCode Therapeutics, Inc. Announces Proposed Public Offering of Common StockJuly 22, 2024 | globenewswire.comNasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing RequirementsJune 10, 2024 | globenewswire.comRNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q1 2024June 3, 2024 | investorplace.comTransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138May 29, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: TransCode Therapeutics (RNAZ) and Nyxoah (NYXH)May 16, 2024 | markets.businessinsider.comWhy TransCode Therapeutics (RNAZ) Stock Is Getting HammeredMay 13, 2024 | msn.comWhy Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?May 13, 2024 | investorplace.comTransCode Therapeutics Open Letter to ShareholdersMay 13, 2024 | globenewswire.comFDA clears TransCode's drug trial for advanced tumorsApril 17, 2024 | uk.investing.comTransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid TumorsApril 15, 2024 | globenewswire.comPromising Phase 0 Results and Upcoming Trial Boost Confidence in TransCode TherapeuticsApril 4, 2024 | markets.businessinsider.comTransCode Therapeutics Reports 2023 Results; Provides Business UpdateApril 3, 2024 | globenewswire.comTransCode Therapeutics appoints new Chief Medical OfficerMarch 30, 2024 | uk.investing.comTransCode Appoints Daniel Vlock As CMOMarch 29, 2024 | markets.businessinsider.comTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerMarch 28, 2024 | finanznachrichten.deTransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerMarch 28, 2024 | globenewswire.comTransCode Therapeutics, Inc.: TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentMarch 11, 2024 | finanznachrichten.deTransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentMarch 11, 2024 | globenewswire.comTransCode Therapeutics To Present At 2024 RNA Leaders Europe CongressMarch 6, 2024 | globenewswire.comTransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist ImmunotherapeuticFebruary 20, 2024 | finance.yahoo.comTransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist ImmunotherapeuticFebruary 20, 2024 | globenewswire.comTranscode Therapeutics Inc (RNAZ)February 1, 2024 | uk.investing.comNasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock MarketJanuary 31, 2024 | finance.yahoo.comLooking Into TransCode Therapeutics's Recent Short InterestJanuary 30, 2024 | benzinga.comTransCode Collaborates With Debiopharm; Financial Terms Not DisclosedJanuary 29, 2024 | markets.businessinsider.comTransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for CancerJanuary 29, 2024 | finance.yahoo.comTransCode Therapeutics Announces Closing of $7.25 Million Public OfferingJanuary 22, 2024 | finance.yahoo.com Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin RNAZ Media Mentions By Week RNAZ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNAZ News Sentiment▼0.130.47▲Average Medical News Sentiment RNAZ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNAZ Articles This Week▼31▲RNAZ Articles Average Week Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Equillium News Today GeoVax Labs News Today Lakeshore Biopharma News Today BioXcel Therapeutics News Today Calidi Biotherapeutics News Today Cadrenal Therapeutics News Today Lisata Therapeutics News Today Exicure News Today Tempest Therapeutics News Today Chemomab Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNAZ) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAZ Stock Alerts